Hepatitis B Virus-Infected HepG2^hNTCPCells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8⁺T Cells<i>In Vitro</i>

Abstract

CD8(+) T cells are the main effector lymphocytes in the control of hepatitis B virus (HBV) infection. However, limitations of model systems, such as low infection rates, restrict mechanistic studies of HBV-specific CD8(+) T cells. Here, we established a novel immunological cell culture model based on HBV-infected HepG2(hNTCP) cells that endogenously processed viral antigens and presented them to HBV-specific CD8(+) T cells. This induced cytolytic and noncytolytic CD8(+) T-cell effector functions and reduction of viral loads.